Alfredo Puing, MD
Assistant ProfessorCards
About
Research
Publications
2025
Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease
Soni K, Puing A. Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease. Viruses 2025, 17: 752. PMID: 40573343, PMCID: PMC12197619, DOI: 10.3390/v17060752.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInflammatory bowel diseaseCytomegalovirus colitisUlcerative colitisBowel diseaseCorticosteroid-refractory UCInflammatory bowel disease flaresInflammatory bowel disease symptomsCytomegalovirus reactivationColectomy rateImmunosuppressive agentsBiologic therapyTherapeutic challengeAntiviral therapyViral loadAdult patientsClinical outcomesTissue biopsiesChronic inflammationTreatment strategiesTissue PCRDiagnosis hingesCytomegalovirusActive infectionRisk factorsDiagnostic threshold
2024
Correction: Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center
So W, Khalak S, Ho S, Ross J, Dadwal S, Puing A, Nanayakkara D, Kaur A, Taplitz R, Dickter J. Correction: Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center. Infection 2024, 52: 2571-2571. PMID: 39382776, DOI: 10.1007/s15010-024-02410-x.Commentaries, Editorials and LettersImplementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center
So W, Khalak S, Ho S, Ross J, Dadwal S, Puing A, Nanayakkara D, Kaur A, Taplitz R, Dickter J. Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center. Infection 2024, 52: 2279-2286. PMID: 38907094, DOI: 10.1007/s15010-024-02274-1.Peer-Reviewed Original ResearchConceptsDelabel patientsLow riskHigh riskEmpirical antibiotic useLow-risk patientsBroad-spectrum antibioticsNon-verbal patientsPiperacillin-tazobactamAntibiotic historyMild rashAdult patientsClinical outcomesAntibiotic useAllergy labelsComprehensive cancer centerTest-doseCancer CenterMcNemar testPatientsAllergic reactionsInclusion criteriaBlaComfort careDelabelingManagement protocolHIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation
Dickter J, Aribi A, Cardoso A, Gianella S, Gendzekhadze K, Li S, Feng Y, Chaillon A, Laird G, Browning D, Ross J, Nanayakkara D, Puing A, Stan R, Lai L, Chang S, Kidambi T, Thomas S, Al Malki M, Nakamura R, Alvarnas J, Taplitz R, Dadwal S, Forman S, Zaia J. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation. The New England Journal Of Medicine 2024, 390: 669-671. PMID: 38354149, PMCID: PMC10906479, DOI: 10.1056/nejmc2312556.Commentaries, Editorials and LettersConceptsHIV-1 remissionHIV-1History of HIV-1 infectionAllogeneic hematopoietic-cell transplantationTreatment of acute myelogenous leukemiaHIV-1 infectionStem-cell transplantationHematopoietic-cell transplantationAcute myelogenous leukemiaA patientsMyelogenous leukemiaRemissionTransplantationLeukemiaInfection
2023
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Chiuppesi F, Ortega-Francisco S, Gutierrez M, Li J, Ly M, Faircloth K, Mack-Onyeike J, La Rosa C, Thomas S, Zhou Q, Drake J, Slape C, Fernando P, Rida W, Kaltcheva T, Grifoni A, Sette A, Patterson A, Dempsey S, Ball B, Ali H, Salhotra A, Stein A, Nathwani N, Rosenzweig M, Nikolaenko L, Al Malki M, Dickter J, Nanayakkara D, Puing A, Forman S, Taplitz R, Zaia J, Nakamura R, Wussow F, Diamond D, Dadwal S. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy. Vaccines 2023, 11: 1492. PMID: 37766168, PMCID: PMC10538048, DOI: 10.3390/vaccines11091492.Peer-Reviewed Original ResearchHematopoietic cell transplantationCellular immune responsesImmune responseMonths post-vaccinationCell transplantationHematologic malignanciesHistorical cohortNeutralizing antibodiesSARS-CoV-2 antigen-specificSARS-CoV-2Post-hematopoietic cell transplantationCD4+ T lymphocytesPhase 2 clinical trialNucleocapsid (N) antigensRobust stimulationsHealthcare workersSARS-CoV-2 infectionHM patientsImmunocompetent individualsImmunocompromised populationsCOH04S1SARS-CoV-2 ST cellsT lymphocytesCellular immunityTreatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience
Tinajero J, Ngo D, Puing A, Koller P. Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience. Acta Haematologica 2023, 146: 490-495. PMID: 38156364, DOI: 10.1159/000533346.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcute myeloid leukemiaAcute myeloid leukemia induction chemotherapyAcute myeloid leukemia regimensSingle-center experienceAntiretroviral therapyHIV antiretroviral therapyInduction chemotherapyTreatment outcomesComplete remissionMyeloid leukemiaTreatment outcomes of acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationTherapy-related myelodysplastic syndromeOutcomes of acute myeloid leukemiaTreatment of acute myeloid leukemiaConcurrent antiretroviral therapyStem cell transplantationHuman immunodeficiency virusPotential drug interactionsMedian OSCR rateMyelodysplastic syndromeCell transplantationChemotherapy exposureUse of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience
Amanam I, Yao J, Puing A, Tsai N, Samuels D, Ngo D, Ho S, Ali H, Aribi A, Arslan S, Artz A, Htut M, Koller P, Salhotra A, Sandhu K, Nikolaenko L, Pawlowska A, Shouse G, Stein A, Marcucci G, Forman S, Nakamura R, Dadwal S, Al Malki M. Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience. Cancer Medicine 2023, 12: 11248-11253. PMID: 37081733, PMCID: PMC10242327, DOI: 10.1002/cam4.5832.Peer-Reviewed Original ResearchConceptsMild to moderate COVID-19Hematological patientsEmergency use authorizationMAb infusionHematologic malignanciesCohort patientsDisease progressionMedian time to clearanceHigh riskRetrospective single-center experienceSingle-center experienceMonoclonal antibody therapyAdult hematology patientsTime to clearanceSARS-CoV-2Non-HCTAntibody therapyMedian delayCasirivimab-imdevimabViral sheddingPatientsSevere diseaseMonoclonal antibodiesTherapySpecific mAbs
2022
Oesophageal and pulmonary invasive aspergillosis in a patient with multiple myeloma
Puing A, Ross J, Parekh V, Nanayakkara D. Oesophageal and pulmonary invasive aspergillosis in a patient with multiple myeloma. BMJ Case Reports 2022, 15: e246403. PMID: 35318199, PMCID: PMC8943765, DOI: 10.1136/bcr-2021-246403.Peer-Reviewed Original ResearchConceptsInvasive aspergillosisDisseminated IAMultiple myelomaAdvanced casesHigh indexHigh index of suspicionAssociated with high morbidityPulmonary invasive aspergillosisRefractory multiple myelomaIndex of suspicionCell-mediated immunityGastrointestinal aspergillosisFebrile neutropeniaOesophageal involvementImaging findingsHigh morbidityInvasive proceduresAspergillosisFungal infectionsEarly diagnosisPoor specificityPatientsTherapeutic interventionsGastrointestinal tractMolecular diagnosticsSuccessful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity
Pourhassan H, La Rosa C, Chiuppesi F, Puing A, Aldoss I, Park Y, Zhou Q, Karpinski V, Faircloth K, Kaltcheva T, Johnson D, Francisco S, Zaia J, Nakamura R, Al Malki M, Diamond D, Dadwal S, Forman S. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. Blood Advances 2022, 6: 1645-1650. PMID: 35008104, PMCID: PMC8752192, DOI: 10.1182/bloodadvances.2021006282.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT cellsCellular immunitySARS-CoV-2-specific cellular immunitySARS-CoV-2-specific T cellsAllogeneic hematopoietic stem cell transplantationSARS-CoV-2Impact of targeted therapiesHematopoietic stem cell transplant patientsAcute lymphoblastic leukemia patientsAdaptive cellular therapyStem cell transplantationT cell responsesLymphoblastic leukemia patientsReverse transcriptase polymerase chain reactionCellular immune responsesTranscriptase polymerase chain reactionSusceptibility to COVID-19 diseaseSARS-CoV-2 infectionTransplant immunosuppressionCell transplantationClinical courseDonor vaccinationLeukemia patientsCellular therapySafety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
Chiuppesi F, Zaia J, Frankel P, Stan R, Drake J, Williams B, Acosta A, Francis K, Taplitz R, Dickter J, Dadwal S, Puing A, Nanayakkara D, Ash P, Cui Y, Contreras H, La Rosa C, Tiemann K, Park Y, Medina J, Iniguez A, Zhou Q, Karpinski V, Johnson D, Faircloth K, Kaltcheva T, Nguyen J, Kha M, Nguyen V, Francisco S, Grifoni A, Wong A, Sette A, Wussow F, Diamond D. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. The Lancet Microbe 2022, 3: e252-e264. PMID: 35287430, PMCID: PMC8906816, DOI: 10.1016/s2666-5247(22)00027-1.Peer-Reviewed Original ResearchConceptsPhase 1 trialVaccinia virus AnkaraPlacebo vaccineVirus AnkaraExact testDay 0SARS-CoV-2 antibodiesCOVID-19 vaccine candidatesHope Comprehensive Cancer CenterDose-expansion cohortsGrade 3 feverOpen-label cohortSevere adverse eventsAdditional secondary outcomesModified vaccinia virus AnkaraT cell responsesBody mass indexNegative pregnancy testComprehensive cancer centerSARS-CoV-2 spikeNucleocapsid-specific antibodiesFisher's exact testCOVID-19 vaccineSARS-CoV-2Plaque-forming units
Academic Achievements & Community Involvement
Clinical Care
Overview
Alfredo Puing, MD, is an infectious diseases and internal medicine specialist who focuses on improving outcomes for patients with infectious diseases, especially those who are immunocompromised.
Dr. Puing received his medical training from Universidad Central del Ecuador and completed his residency in internal medicine at Saint Peter's University Hospital in New Jersey. He further specialized through fellowships in infectious diseases at the University of Texas Southwestern Medical Center and Stanford University. He is an assistant professor at Yale School of Medicine.
Clinical Specialties
Infectious Diseases; Internal Medicine
Fact Sheets
Sepsis
Learn More on Yale MedicinePediatric Sepsis
Learn More on Yale MedicinePneumonia
Learn More on Yale Medicine
Board Certifications
Infectious Disease
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2019
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2017
Yale Medicine News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.